Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

Monoclonal antibody biosimilars

Nature Reviews Drug Discovery volume 15, pages 13–14 (2016)Cite this article

Subjects

Emergence of mAb biosimilars

This is a preview of subscription content, access via your institution

Relevant articles

Open Access articles citing this article.

Access options

Rent or buy this article

Get just this article for as long as you need it

$39.95

Learn more

Prices may be subject to local taxes which are calculated during checkout

Figure 1: Three models of US biosimilar adoption.

Author information

Authors and Affiliations

  1. Trinity Partners, 90 New Montgomery Street, Suite 650, San Francisco, 94105, California, USA

    Natasha Udpa & Ryan P. Million

Authors
  1. Natasha Udpa
    View author publications

    You can also search for this author in PubMed Google Scholar

  2. Ryan P. Million
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding authors

Correspondence to Natasha Udpa or Ryan P. Million.

Ethics declarations

Competing interests

The authors declare no competing financial interests.

Related links

PowerPoint slides

Supplementary information

Supplementary information S1 (box)

Data and analysis for Figure 1 (PDF 2118 kb)

Rights and permissions

Reprints and Permissions

About this article

Verify currency and authenticity via CrossMark

Cite this article

Udpa, N., Million, R. Monoclonal antibody biosimilars. Nat Rev Drug Discov 15, 13–14 (2016). https://doi.org/10.1038/nrd.2015.12

Download citation

  • Published:

  • Issue Date:

  • DOI: https://doi.org/10.1038/nrd.2015.12

This article is cited by

Search

Advanced search

Quick links

Nature Briefing: Translational Research

Sign up for the Nature Briefing: Translational Research newsletter — top stories in biotechnology, drug discovery and pharma.

Get what matters in translational research, free to your inbox weekly. Sign up for Nature Briefing: Translational Research